Stockreport

Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity [Yahoo! Finance]

Humacyte, Inc.  (HUMA) 
PDF On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 result [Read more]